 |
Press ReleasesSQI Diagnostics Inc. Receives ISO 13485 CertificationReleased: Jun 09, 2008 Toronto, Ontario, June 9, 2008 – SQI Diagnostics Inc. (TSX-Venture: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it has been awarded its ISO 13485:2003 certification for its quality management system for the Design and Development, Production, Distribution, Installation and Servicing of its In Vitro Diagnostics systems (Microarray Platforms and Consumable Kits). This significant milestone further reinforces SQI Diagnostics’ efforts to develop and manufacture high-quality medical systems and tests for the healthcare market.
ISO Certification ISO Certification ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to develop, manufacture and service medical devices that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services. About SQI Diagnostics For further information please contact:
Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. This release was prepared by management of the Company who takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. |
"The certification and implementation of a Quality Management System in accordance with ISO 13485 demonstrates that we are well positioned to manufacture and distribute our SQiDworks™ platform and QuantiSpot™ panels at the standards required by our international customers," said Claude Ricks, CEO of SQI Diagnostics. "This accomplishment brings us a step closer to commercialization of our first products. We expect to complete the validation studies of our automated microarray platform and multiplexed rheumatoid arthritis test panel in the coming months."